• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Response to Gomez et al.'s Letter to the Editor Regarding: "Cost-Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Versus Lower-Valent Alternatives in Filipino Infants".

作者信息

Perdrizet Johnna, Horn Emily, Nua Winniefer, Perez-Peralta Judith, Nailes Jennifer, Santos Jaime, Ong-Lim Anna

机构信息

Global Health Economics and Outcomes Research, Pfizer Inc., 235 42nd Street, New York, NY, 10017, USA.

Pfizer Inc., Makati City, Philippines.

出版信息

Infect Dis Ther. 2022 Aug;11(4):1763-1765. doi: 10.1007/s40121-022-00641-9. Epub 2022 May 16.

DOI:10.1007/s40121-022-00641-9
PMID:35575973
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9334460/
Abstract
摘要

相似文献

1
Response to Gomez et al.'s Letter to the Editor Regarding: "Cost-Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Versus Lower-Valent Alternatives in Filipino Infants".对戈麦斯等人就《13价肺炎球菌结合疫苗（PCV13）与低价替代疫苗在菲律宾婴儿中的成本效益》致编辑信的回复。
Infect Dis Ther. 2022 Aug;11(4):1763-1765. doi: 10.1007/s40121-022-00641-9. Epub 2022 May 16.
2
A Response to: Letter to the Editor Regarding "Cost-Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Versus Lower-Valent Alternatives in Filipino Infants".对《致编辑的信：关于“13价肺炎球菌结合疫苗（PCV13）与低剂量替代疫苗在菲律宾婴儿中的成本效益”》的回应
Infect Dis Ther. 2022 Jun;11(3):1301-1303. doi: 10.1007/s40121-022-00639-3. Epub 2022 Apr 26.
3
Letter to the Editor Regarding: "Cost-Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Versus Lower-Valent Alternatives in Filipino Infants".致编辑的信：关于“13价肺炎球菌结合疫苗（PCV13）与低价位替代疫苗在菲律宾婴儿中的成本效益比较”
Infect Dis Ther. 2022 Aug;11(4):1757-1761. doi: 10.1007/s40121-022-00640-w. Epub 2022 May 16.
4
Comment on Gomez et. al. "Response to article by Wasserman et. al. (2018) 'Modelling the sustained use of the 13-valent pneumococcal conjugate vaccine compared to switching to the 10-valent vaccine in Mexico'".评论戈麦斯等人的文章“对 Wasserman 等人（2018 年）文章的回应：对墨西哥使用 13 价肺炎球菌结合疫苗替代 10 价疫苗的持续使用进行建模”。
Hum Vaccin Immunother. 2019;15(3):572-574. doi: 10.1080/21645515.2018.1558691. Epub 2019 Jan 18.
5
Cost-Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Versus Lower-Valent Alternatives in Filipino Infants.13价肺炎球菌结合疫苗（PCV13）与低价替代疫苗在菲律宾婴儿中的成本效益比较
Infect Dis Ther. 2021 Dec;10(4):2625-2642. doi: 10.1007/s40121-021-00538-z. Epub 2021 Sep 30.
6
Reply letter to "response to article by Johnna Perdrizet et al." by Gomez and colleagues.致 Gomez 等人对 Johnna Perdrizet 等人文章的回应的回复信。
Hum Vaccin Immunother. 2022 Dec 31;18(1):1917237. doi: 10.1080/21645515.2021.1917237. Epub 2021 Apr 28.
7
Cost-Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Versus Lower-Valent Alternatives in Filipino Infants.13价肺炎球菌结合疫苗（PCV13）与低价替代疫苗在菲律宾婴儿中的成本效益分析
Infect Dis Ther. 2022 Jun;11(3):1297-1299. doi: 10.1007/s40121-022-00643-7. Epub 2022 Apr 28.
8
Evaluation of 13-valent pneumococcal conjugate vaccine and concomitant meningococcal group C conjugate vaccine in healthy infants and toddlers in Spain.西班牙健康婴儿和幼儿中 13 价肺炎球菌结合疫苗和同时接种的脑膜炎球菌 C 群结合疫苗的评估。
Vaccine. 2013 Nov 4;31(46):5486-94. doi: 10.1016/j.vaccine.2013.06.049. Epub 2013 Sep 1.
9
Cost-effectiveness of a national immunization program with the 13-valent pneumococcal conjugate vaccine compared with the 10-valent pneumococcal conjugate vaccine in South Korea.在韩国，13价肺炎球菌结合疫苗与10价肺炎球菌结合疫苗的国家免疫规划的成本效益比较。
Hum Vaccin Immunother. 2021 Mar 4;17(3):909-918. doi: 10.1080/21645515.2020.1796426. Epub 2020 Aug 12.
10
Cost-effectiveness of administering 13-valent pneumococcal conjugate vaccine in addition to 23-valent pneumococcal polysaccharide vaccine to adults with immunocompromising conditions.免疫功能低下成人患者中，接种 13 价肺炎球菌结合疫苗替代 23 价肺炎球菌多糖疫苗的成本效益分析。
Vaccine. 2013 Dec 5;31(50):6011-21. doi: 10.1016/j.vaccine.2013.10.024. Epub 2013 Oct 19.

本文引用的文献

1
Letter to the editor regarding "Budget impact analysis of pneumococcal conjugate vaccines in Colombia".
Expert Rev Pharmacoecon Outcomes Res. 2022 Jan;22(1):1-3. doi: 10.1080/14737167.2022.1986006. Epub 2021 Oct 4.
2
Reply letter to "response to article by Johnna Perdrizet et al." by Gomez and colleagues.致 Gomez 等人对 Johnna Perdrizet 等人文章的回应的回复信。
Hum Vaccin Immunother. 2022 Dec 31;18(1):1917237. doi: 10.1080/21645515.2021.1917237. Epub 2021 Apr 28.
3
Retrospective Impact Analysis and Cost-Effectiveness of the Pneumococcal Conjugate Vaccine Infant Program in Australia.澳大利亚肺炎球菌结合疫苗婴儿计划的回顾性影响分析及成本效益
Infect Dis Ther. 2021 Mar;10(1):507-520. doi: 10.1007/s40121-021-00409-7. Epub 2021 Feb 11.
4
Cost-effectiveness analysis of replacing the 10-valent pneumococcal conjugate vaccine (PCV10) with the 13-valent pneumococcal conjugate vaccine (PCV13) in Brazil infants.在巴西婴儿中用13价肺炎球菌结合疫苗（PCV13）替代10价肺炎球菌结合疫苗（PCV10）的成本效益分析。
Hum Vaccin Immunother. 2021 Apr 3;17(4):1162-1172. doi: 10.1080/21645515.2020.1809266. Epub 2020 Sep 23.
5
Estimating the Impact of Switching from a Lower to Higher Valent Pneumococcal Conjugate Vaccine in Colombia, Finland, and The Netherlands: A Cost-Effectiveness Analysis.评估在哥伦比亚、芬兰和荷兰从低价次向高价次肺炎球菌结合疫苗转换的影响：一项成本效益分析。
Infect Dis Ther. 2020 Jun;9(2):305-324. doi: 10.1007/s40121-020-00287-5. Epub 2020 Feb 24.
6
Estimating the Clinical and Economic Impact of Switching from the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) to the 10-Valent Pneumococcal Conjugate Vaccine (PCV10) in Italy.评估在意大利从13价肺炎球菌结合疫苗（PCV13）转换为10价肺炎球菌结合疫苗（PCV10）的临床和经济影响。
Pathogens. 2020 Jan 22;9(2):76. doi: 10.3390/pathogens9020076.
7
Estimating the population health and economic impacts of introducing a pneumococcal conjugate vaccine in Malaysia- an economic evaluation.在马来西亚引入肺炎球菌结合疫苗的人群健康和经济影响评估- 经济评价。
Hum Vaccin Immunother. 2020 Jul 2;16(7):1719-1727. doi: 10.1080/21645515.2019.1701911. Epub 2020 Jan 17.
8
Comment on Gomez et. al. "Response to article by Wasserman et. al. (2018) 'Modelling the sustained use of the 13-valent pneumococcal conjugate vaccine compared to switching to the 10-valent vaccine in Mexico'".评论戈麦斯等人的文章“对 Wasserman 等人（2018 年）文章的回应：对墨西哥使用 13 价肺炎球菌结合疫苗替代 10 价疫苗的持续使用进行建模”。
Hum Vaccin Immunother. 2019;15(3):572-574. doi: 10.1080/21645515.2018.1558691. Epub 2019 Jan 18.
9
Response to McGirr et al.'s Comment on "Clinical and Economic Impact of a Potential Switch from 13-Valent to 10-Valent Pneumococcal Conjugate Infant Vaccination in Canada".对麦吉尔等人就《加拿大13价肺炎球菌结合疫苗转为10价肺炎球菌结合疫苗对婴儿接种的临床和经济影响》一文的评论的回应。
Infect Dis Ther. 2018 Dec;7(4):539-543. doi: 10.1007/s40121-018-0221-2. Epub 2018 Nov 8.
10
Modeling the sustained use of the 13-valent pneumococcal conjugate vaccine compared to switching to the 10-valent vaccine in Mexico.建立模型以比较 13 价肺炎球菌结合疫苗在墨西哥的持续使用与切换至 10 价疫苗的情况。
Hum Vaccin Immunother. 2019;15(3):560-569. doi: 10.1080/21645515.2018.1516491. Epub 2018 Sep 21.